Ginkgo Bioworks Holdings, Inc. (DNA)
$
10.63
+0.36 (3.39%)
Key metrics
Financial statements
Free cash flow per share
-4.9977
Market cap
629.3 Million
Price to sales ratio
2.7264
Debt to equity
0.6996
Current ratio
5.4076
Income quality
0.7542
Average inventory
0
ROE
-0.4544
Technology
Technology – consumer electronics
Largecap
With a market cap of 121,78 bil stock is ranked 1
Low risk
ISS score of this stock is ranked 1
Company description
Profile
Ginkgo Bioworks Holdings, Inc., along with its subsidiaries, specializes in developing a platform for cell programming that facilitates the biological production of various products such as novel therapeutics, food ingredients, and petroleum-derived chemicals. The company serves a diverse range of end markets, including specialty chemicals, agriculture, food, consumer products, and pharmaceuticals. As a testament to its operational performance, the company recorded an operating income of -$559,757,000.00 reflecting its earnings from core operations. The gross profit ratio is 0.83 showcasing the efficiency of the company's production and sales operations, while the gross profit stands at $188,494,000.00 highlighting its profitability from core activities. The company's stock is identified with the symbol 'DNA' in the market, and the operating income ratio is -2.47 indicating the company's operational profitability margin. Additionally, Ginkgo Bioworks has established a partnership with Selecta Biosciences, Inc. to advance the ImmTOR technology platform. Founded in 2008, the company is headquartered in Boston, Massachusetts. In the market landscape, the stock is affordable at $11.02 catering to budget-conscious investors. With a high average trading volume of 1,692,704.00 the stock indicates strong liquidity, making it an appealing option for traders. Ginkgo Bioworks, classified as a small-cap player with a market capitalization of $629,293,874.00 is a key player in the Biotechnology industry, contributing significantly to the overall market landscape. It belongs to the Healthcare sector, driving innovation and growth while playing a vital role in shaping future developments in its field.
Is Ginkgo Bioworks Holdings, Inc. (DNA) a good investment?
Investing in Ginkgo Bioworks Holdings, Inc. (DNA) depends on multiple factors, including revenue growth, profit margins, debt-to-equity ratio, earnings per share, and return on equity. Analysts have rated it as C-, with a Bearish outlook. Always conduct your own research before investing.
What is Ginkgo Bioworks Holdings, Inc. (DNA)'s stock forecast?
Analysts predict Ginkgo Bioworks Holdings, Inc. stock to fluctuate between $5 (low) and $16.85 (high) in the next 365 days, reflecting market expectations and potential volatility.
What is Ginkgo Bioworks Holdings, Inc.'s market capitalization?
As of 2025-09-17, Ginkgo Bioworks Holdings, Inc.'s market cap is $629,293,874, based on 59,199,800 outstanding shares.
How does Ginkgo Bioworks Holdings, Inc. compare to competitors like Meta Platforms, Inc. Class A Common Stock?
Compared to Meta Platforms, Inc. Class A Common Stock, Ginkgo Bioworks Holdings, Inc. has a Lower Market-Cap, indicating a difference in performance.
How can I buy Ginkgo Bioworks Holdings, Inc. (DNA) stock?
To buy Ginkgo Bioworks Holdings, Inc. (DNA) stock: Open a brokerage account (e.g., Robinhood, TD Ameritrade, E-Trade). Search for DNA. Place an order (Market, Limit, etc.).
What is the best time to invest in Ginkgo Bioworks Holdings, Inc.?
The best time to invest depends on market trends and technical indicators, which show a Bearish trend based on economic conditions and company performance.
Has Ginkgo Bioworks Holdings, Inc. stock ever split?
Ginkgo Bioworks Holdings, Inc.'s last stock split was 1:40 on 2024-08-20.
How did Ginkgo Bioworks Holdings, Inc. perform in the last earnings report?
Revenue: $227,043,000 | EPS: -$10.54 | Growth: -42.62%.
Where can I find Ginkgo Bioworks Holdings, Inc.'s investor relations reports?
Visit https://www.ginkgobioworks.com/investor-relations for detailed financial reports.
Where can I find historical stock prices for Ginkgo Bioworks Holdings, Inc.?
You can explore historical data from here
What is the all-time high and low for Ginkgo Bioworks Holdings, Inc. stock?
All-time high: $634.56 (2021-11-09) | All-time low: $5 (2025-04-04).
What are the key trends affecting Ginkgo Bioworks Holdings, Inc. stock?
Key trends include market demand, economic conditions, interest rates, and industry competition, which influence the stock's performance.
News
prnewswire.com
BOSTON , Aug. 29, 2025 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA) today released the following notice: UNITED STATES DISTRICT COURT NORTHERN DISTRICT OF CALIFORNIA OAKLAND DIVISION WEINING HU, derivatively on behalf of GINKGO BIOWORKS HOLDINGS, INC., a Delaware corporation, Plaintiff, vs.
prnewswire.com
SECAUCUS, N.J. , Aug. 25, 2025 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), a leading provider of diagnostic information services, today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Device Designation for the company's Haystack MRD® test for identifying MRD-positive patients with stage II colorectal cancer following curative-intent surgical treatment who may benefit from adjuvant therapy in accordance with therapeutic product labeling.
seekingalpha.com
Ginkgo Bioworks' shares have rallied tremendously, and Q2 results showed a headline revenue beat with no upward guidance revision. Biosecurity segment guidance was cut, and overall revenue estimates have plunged, raising concerns about future growth. Despite cost reductions, Ginkgo continues to post large operating losses and faces ongoing cash burn, prompting a $500 million shelf offering.
seekingalpha.com
Ginkgo Bioworks Holdings, Inc. (NYSE:DNA ) Q2 2025 Earnings Conference Call August 7, 2025 5:30 PM ET Company Participants Daniel Waid Marshall - Senior Manager of Communications and Ownership Jason Kelly - Founder, CEO & Director Steven P. Coen - Chief Accounting Officer & CFO Daniel Waid Marshall Good evening.
prnewswire.com
Ginkgo provides an update on its restructuring, including achievement of its expanded $250 million cost savings targets BOSTON , Aug. 7, 2025 /PRNewswire/ -- Ginkgo Bioworks Holdings, Inc. (NYSE: DNA, "Ginkgo"), which is building the leading platform for cell programming and biosecurity, today announced its results for the second quarter ended June 30, 2025. The update, including a webcast slide presentation with additional details on the second quarter, as well as supplemental financial information will be available at investors.ginkgobioworks.com.
zacks.com
Ginkgo Bioworks Holdings, Inc. (DNA) concluded the recent trading session at $13.96, signifying a -6.31% move from its prior day's close.
zacks.com
Ginkgo Bioworks Holdings, Inc. (DNA) concluded the recent trading session at $9.6, signifying a +1.8% move from its prior day's close.
zacks.com
In the closing of the recent trading day, Ginkgo Bioworks Holdings, Inc. (DNA) stood at $10.79, denoting a -2.53% move from the preceding trading day.
benzinga.com
Meta Platforms, Inc. META CEO Mark Zuckerberg has made a decisive move to reshape the company's entire AI strategy by consolidating all artificial intelligence efforts under a newly formed division called Meta Superintelligence Labs.
accessnewswire.com
Division of Silver Scott Mines, Inc. Expands Health and Wellness Offerings FRANKLIN, NJ / ACCESS Newswire / June 24, 2025 / Silver Scott Health, Inc., a division of Silver Scott Mines, Inc. (OTC PINK:SILS), today announced a distribution agreement with DNA Vibe, the innovator behind patented red light therapy devices. Beginning in the third quarter, DNA Vibe's wearable wellness technology will be available for purchase on the Silver Scott Health website, furthering the company's mission to bring scientifically-backed, non-invasive health and wellness solutions to consumers.
See all news
